Drug Bioavailability

What bioavailability actually measures

Bioavailability answers a deceptively simple question: of the dose you gave, how much actually made it into the bloodstream where it can do its job? The two things it captures are extent (what fraction got there) and, in its full form, rate (how fast). Both matter. A drug that is fully absorbed but absorbed slowly behaves very differently — lower peak, later peak — than the same drug absorbed quickly, even if the total amount is identical.

The extent of absorption is quantified by the area under the concentration-time curve (AUC). If you give a drug, draw blood at intervals, and plot plasma concentration against time, the area swept out under that curve is proportional to the total amount of drug that reached the systemic circulation. The rate is captured by two related numbers: C_max, the peak concentration reached, and T_max, the time at which the peak occurs.

Because intravenous administration delivers the entire dose directly into the blood with no absorption barrier, it is the benchmark. Absolute bioavailability is defined as:

F = (AUC_oral / dose_oral) ÷ (AUC_IV / dose_IV)

If a 100 mg oral dose produces three-quarters of the exposure (AUC) of a 100 mg IV dose, then F = 0.75, or 75%. Relative bioavailability drops the IV arm and instead compares two non-intravenous formulations — a generic tablet versus the brand, a tablet versus a capsule, fed versus fasted. This is the engine of bioequivalence testing.

The journey of a swallowed pill

Picture a 100 mg tablet going down. Several toll-gates stand between the pill and the systemic circulation, and at each one a fraction is lost:

• Disintegration and dissolution. A solid tablet must break apart and dissolve before any drug can be absorbed. Poorly soluble drugs (a large share of modern candidates) may simply pass through undissolved. This is why formulation — particle size, salt form, excipients — can change bioavailability dramatically without changing the molecule.
• Survival in the gut lumen. Gastric acid degrades acid-labile drugs (penicillin G, insulin and other peptides). Digestive and bacterial enzymes destroy others. This is the reason insulin cannot simply be swallowed.
• Absorption across the intestinal wall. The drug must cross the enterocyte membrane, usually by passive diffusion, which favors lipophilic, un-ionized molecules. Highly polar or large molecules are absorbed poorly. Efflux transporters such as P-glycoprotein actively pump some drugs back into the lumen, capping absorption.
• Gut-wall metabolism. The enterocytes themselves contain CYP3A4 and conjugating enzymes that metabolize drug before it ever reaches the portal blood — a pre-systemic loss that is part of the broader first-pass effect.
• Hepatic first-pass. Everything absorbed from the gut drains into the portal vein and is delivered to the liver before reaching the systemic circulation. For drugs the liver extracts efficiently, most of the absorbed dose is metabolized on this single pass. Only what survives enters the hepatic vein and then the heart and the rest of the body.

The overall oral bioavailability is the product of the fraction surviving each step: F = f_absorbed × f_gut × f_hepatic. A drug can be perfectly absorbed (f_absorbed ≈ 1) and still have a low F if the liver extracts 80% of it on first pass.

First-pass metabolism and hepatic extraction

The single biggest reason oral and IV doses differ is the first-pass effect. The key parameter is the hepatic extraction ratio (E) — the fraction of drug removed during one transit through the liver. For a drug absorbed completely, oral bioavailability from the hepatic step alone is approximately (1 − E).

• High-extraction drugs (E > 0.7). Propranolol, morphine, lidocaine, verapamil, and glyceryl trinitrate. Their oral bioavailability is low and, importantly, sensitive to liver blood flow. In cirrhosis or heart failure, where portal flow is reduced or shunted around the liver, first-pass extraction falls and bioavailability rises — sometimes dangerously.
• Low-extraction drugs (E < 0.3). Warfarin, phenytoin, theophylline, diazepam. Their clearance depends on enzyme capacity rather than blood flow, so first-pass loss is modest and oral bioavailability is high. They are instead sensitive to enzyme induction (rifampicin, carbamazepine) or inhibition (azole antifungals, macrolides).

This is why lidocaine is given intravenously for arrhythmias but never orally for that purpose — heavy first-pass extraction leaves an oral bioavailability of only about 35%, and the metabolites it generates (MEGX, GX) accumulate and can be toxic. It is why glyceryl trinitrate for angina is placed under the tongue: the sublingual mucosa drains into the superior vena cava, bypassing the portal vein and the liver entirely, so a tiny dose reaches the heart within seconds. Rectal administration partially bypasses first-pass too, because the lower rectal veins drain into the systemic circulation rather than the portal system.

AUC, the IV reference, and computing F

The animation that accompanies this article makes the AUC idea concrete: an IV dose produces a tall, fast-falling concentration curve whose full area represents 100% of the dose; the same drug given orally produces a lower, rounder curve whose smaller area represents the fraction that survived. The ratio of those two areas is the bioavailability.

A few practical points often confused even by clinicians:

• Rate vs extent are separable. A controlled-release tablet may have the same AUC (same extent, same F) as an immediate-release tablet but a much lower, later C_max. The total drug delivered is identical; the shape differs.
• F cannot exceed 1.0. For any extravascular route, bioavailability relative to IV is capped at 100%, because you cannot deliver more than the whole dose to the blood. An apparent F above 1.0 signals a flawed comparison (wrong reference dose, non-linear kinetics, or assay error), not a real effect.
• Food matters. Food can raise bioavailability (it stimulates bile, helping dissolve lipophilic drugs like itraconazole) or lower it (chelation of tetracyclines and fluoroquinolones by calcium, iron, and magnesium can cut absorption by half or more).

Routes of administration compared

The route you choose largely determines bioavailability before the molecule is even involved. The table below summarizes the trade-offs.

Route	Typical bioavailability (F)	First-pass?	Onset	Why used
Intravenous (IV)	100% (reference)	No	Seconds	Emergencies, exact titration, drugs destroyed orally
Intramuscular / subcutaneous	75–100% (depot variable)	No	Minutes–hours	Vaccines, depot formulations, when IV access is hard
Sublingual / buccal	High for suited drugs	Bypassed	Seconds–minutes	Nitroglycerin for angina, opioid breakthrough pain
Oral (PO)	5–100%, drug-specific	Yes (full)	30 min–2 h	Convenient, default for chronic therapy
Rectal	Variable, ~50% first-pass spared	Partial	Variable	Vomiting, seizures, pediatrics
Transdermal	Slow, near-complete over time	Bypassed	Hours	Steady delivery (fentanyl, nicotine, estrogen patches)

Clinical consequences

• IV-to-oral conversion. When a hospitalized patient improves and is switched from IV to oral therapy, the oral dose must be divided by F to maintain the same systemic exposure. Morphine, with oral F ≈ 0.25, needs roughly 3× the IV dose when given by mouth. Drugs with F > 90% and reliable absorption — levofloxacin, fluconazole, metronidazole, linezolid — can be switched at the same dose, which is a key driver of early hospital discharge.
• Drug-drug and drug-food interactions. Inhibiting CYP3A4 (grapefruit juice, ketoconazole, clarithromycin) raises the bioavailability of CYP3A4 substrates, sometimes severalfold — a normal dose of simvastatin can become a toxic one. Inducing CYP3A4 (rifampicin, St. John's wort) does the opposite, dropping levels of oral contraceptives or immunosuppressants until they fail.
• Liver disease. In cirrhosis, portosystemic shunting lets high-extraction drugs bypass hepatic metabolism, so the oral bioavailability of propranolol, morphine, and similar drugs can rise dramatically. Standard doses can produce exaggerated, prolonged effects.
• Generic substitution. A generic must demonstrate bioequivalence to the reference product — the 90% confidence interval for the ratio of AUC and C_max must lie within 80–125%. For narrow-therapeutic-index drugs (warfarin, levothyroxine, some antiepileptics), even differences inside this band can matter clinically, which is why brand-to-generic switches are watched carefully.
• Formulation as a drug-development lever. When a promising molecule has poor bioavailability, chemists reach for prodrugs (enalapril is the inactive ester of enalaprilat, made orally absorbable), salt changes, nanoparticle or lipid formulations, or absorption enhancers — all to push F higher without altering the active species.

Common misconceptions

• "Bioavailability is the same as absorption." No — absorption is only the first step. A drug can be 100% absorbed yet have low bioavailability if the liver destroys most of it on first pass.
• "Higher bioavailability is always better." Not necessarily. It must be consistent. An erratic F that swings with food or co-medication is more dangerous than a low but predictable one, because doses can't be set reliably.
• "IV and oral doses should be the same." Only when F approaches 100%. For high-extraction drugs the oral dose must be much larger to compensate for first-pass loss.
• "AUC tells you the peak." AUC reflects total exposure (extent), not the peak. Two formulations can share an AUC while having very different C_max and T_max.
• "Grapefruit only matters for a few drugs." Intestinal CYP3A4 metabolizes a large swath of oral drugs; grapefruit inhibition can meaningfully raise exposure for many statins, calcium-channel blockers, and immunosuppressants.

This article is educational and is not medical advice. Dosing decisions and route selection must be made by a qualified clinician for the individual patient.